Recent clinical data highlight that COVID-19 vaccine effectiveness remains a critical factor in patient care. Consequently, a target trial emulation study recently evaluated the updated 2024-2025 mRNA vaccine. This research specifically focused on preventing emergency department visits and hospitalizations. Ultimately, the findings provide vital insights for healthcare providers managing the current respiratory season.

Researchers emulated a target trial using electronic health records from a large South Carolina health system. They compared adults who received the updated 2024-2025 vaccine with those who remained unvaccinated. To ensure accuracy, the team utilized propensity score matching based on demographic and clinical covariates. This approach allowed for a robust comparison of outcomes between the two groups over several months.

The study results revealed that the mRNA vaccine offered significant protection. Specifically, the vaccine was 41.3% effective against emergency department visits or more severe care. Moreover, it demonstrated 46.1% effectiveness against hospital admissions. Notably, these benefits persisted despite high levels of prior immunity from infections or earlier vaccinations. Therefore, the updated dose provides essential protection against severe disease.

Evaluating COVID-19 Vaccine Effectiveness in 2025

These findings demonstrate that moderate protection remains achievable with current boosters. However, the study noted low vaccine uptake in the rural populations of South Carolina. This trend underscores a significant challenge for public health officials. Because emerging variants continue to circulate, clinicians must advocate for sustained vaccination efforts. This is particularly important for older adults and patients with multiple medical comorbidities.

Furthermore, the data suggest the vaccine offers significant incremental protection. Even in populations with significant prior exposure, the updated dose reduces the risk of severe disease. Consequently, healthcare providers should continue to recommend the updated mRNA vaccine to eligible patients. This strategy helps minimize the overall burden on hospital systems during peak periods.

Frequently Asked Questions

How effective is the 2024-2025 COVID-19 vaccine against hospitalization?

The study indicates that the 2024-2025 mRNA vaccine is 46.1% effective against hospitalization. This level of protection is vital for preventing severe clinical outcomes during the respiratory virus season.

Does the vaccine work if I have already had a COVID-19 infection?

Yes, research shows that the vaccine provides additional protection even in populations with high levels of prior infection. It serves as an important booster against current circulating variants.

Is the vaccine effective against emergency department visits?

The updated vaccine demonstrated 41.3% effectiveness against emergency department visits or more severe care. This protection helps reduce the strain on emergency medical services and urgent care centers.

Disclaimer: This content is for informational and educational purposes only. It does not constitute professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified healthcare provider with any questions you may have regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.

References

1. Jayawardena I et al. 2024-2025 COVID-19 mRNA Vaccine Effectiveness against Severe Disease. J Infect Dis. 2026 Mar 02. doi: undefined. PMID: 41766610.


2. Link-Gelles R et al. Interim Estimates of 2024–2025 COVID-19 Vaccine Effectiveness Among Adults Aged ≥18 Years — VISION and IVY Networks, September 2024–January 2025. MMWR Morb Mortal Wkly Rep. 2025 Feb 27.


3. Adams K et al. Estimated Effectiveness of 2024-2025 COVID-19 Vaccination Against Severe COVID-19. JAMA Netw Open. 2026 Feb 03. doi:10.1001/jamanetworkopen.2025.57415.